DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol

Abstract Background Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia. Between 10 and 40% patients experience grade 3–4 (≥ G3) toxic...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Cassandra White, Hannah Wardill, Christine Paul, Timothy Price, Christos Karapetis, Mark Nalder, Matthew E. Burge, Ann Thomas, Chris Oldmeadow, Daniel Barker, Laura C. Edney, Janet Coller, Joanne Bowen, Cheri Ostroff, Bruce Cheek, Mel Carlson, Trumaine Rankmore, Adnan Nagrial, Stephen Clarke, Lorraine Chantrill, Stephen Ackland, Rodney J. Scott
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-11-01
Edice:	BMC Cancer
Témata:	DPYD Fluoropyrimidine Pharmacogenomics Dihydropyrimidine dehydrogenase UGT1A1 Irinotecan
On-line přístup:	https://doi.org/10.1186/s12885-024-13122-8
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!